<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180973</url>
  </required_header>
  <id_info>
    <org_study_id>VUMCA2</org_study_id>
    <secondary_id>CSET 94/346</secondary_id>
    <nct_id>NCT00180973</nct_id>
  </id_info>
  <brief_title>PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.</brief_title>
  <official_title>MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY&#xD;
      (BEC REGIMEN) FOLLOWED BY STANDARD RADIOTHERAPY (70 Gy / 7 WEEKS) VERSUS THE SAME NEOADJUVANT&#xD;
      CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE&#xD;
      TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE (UCNT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 1995</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 year overall survival rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progresion and local control at 2 years</measure>
  </secondary_outcome>
  <enrollment>520</enrollment>
  <condition>LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  of either sex&#xD;
&#xD;
          -  aged *15 and * 70 years&#xD;
&#xD;
          -  never previously treated with radiotherapy, chemotherapy or surgery for malignant&#xD;
             disease (except neck adenectomy/diagnosis)&#xD;
&#xD;
          -  with aWHO performance status * 2.&#xD;
&#xD;
          -  amenable to regular follow-up&#xD;
&#xD;
          -  capable of receiving chemotherapy and radiotherapy : in particular, with no&#xD;
             contraindications to the use of anthracyclines, bleomycin or cisplatinum.&#xD;
&#xD;
          -  with informed consent at entry time, in writing or witnessed oral informed consent, in&#xD;
             accordance with local legislation requirements.&#xD;
&#xD;
          -  Laboratory requirement : *Baseline hematologic status :&#xD;
&#xD;
        Neutrophil count * 2000 /mm3 Platelet count * 150,000 /mm3 Hemoglobin * 10 g / dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histologic types other than type II - III of the WHO classification&#xD;
&#xD;
          -  T1 - T2 N0 - N1 or patients with metastatic&#xD;
&#xD;
          -  Aged &lt; 15 or &gt; 70.&#xD;
&#xD;
          -  Patients in whom chemotherapy is contraindicated: history of myocardial infarction&#xD;
             over the last 6 months before inclusion, or clinically present cardiac pathology.&#xD;
&#xD;
          -  WHO Performance status &gt;2&#xD;
&#xD;
          -  History of prior malignancies (other than non melanoma skin cancer or excised cervical&#xD;
             carcinoma in situ).&#xD;
&#xD;
          -  Uncontrolled infection,&#xD;
&#xD;
          -  Patients refusing participation.&#xD;
&#xD;
          -  Patients who, for social, familial or geographic reasons are unlikely to comply with a&#xD;
             long term follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fran√ßois ESCHWEGE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 13, 2005</last_update_submitted>
  <last_update_submitted_qc>September 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

